Clinical Trials Logo

Drug Safety clinical trials

View clinical trials related to Drug Safety.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05921006 Recruiting - Drug Safety Clinical Trials

Ascending Single-Dose and Multiple-Dose Study to Evaluate RJ4287 in Healthy Subjects

Start date: June 13, 2023
Phase: Phase 1
Study type: Interventional

A Randomized Study of RJ4287 Drug to Evaluate the Safety, Tolerability, Pharmacokinetics and Food-effect of Single and Multiple Doses in Healthy Volunteers

NCT ID: NCT04785027 Recruiting - Psoriasis Clinical Trials

Comparison of PSORI-CM01 Formula vs Gu Ben Hua Yu Formula Combined With AD-MSCs in Psoriasis

Start date: March 17, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to evaluate and compare the safety and efficacy of PSORI-CM01 formula vs Gu Ben Hua Yu formula combined with Expanded Allogeneic AD-MSCs in patients with moderate to severe psoriasis. And it explores the expectations of patients for the treatment of traditional Chinese medicine combined with stem cells and their expectations to participate in this study. The trial would provide preliminary data for large sample clinical randomized controlled trials.

NCT ID: NCT01756183 Recruiting - Drug Safety Clinical Trials

Exploratory Study on the S-1 + Paclitaxel Chemotherapy for Unresectable Gastric Cancer

Start date: September 2011
Phase: Phase 2
Study type: Interventional

Exploratory the S-1 + Paclitaxel Chemotherapy for Creating the Operation Chance in the Patients with Unresectable Gastric Cancer

NCT ID: NCT01301131 Recruiting - Drug Safety Clinical Trials

Probiotics for Prevention of Ventilator-Associated Pneumonia (VAP)

VAP
Start date: December 2011
Phase: Phase 4
Study type: Interventional

Hospitalized patients with ventilator are randomized to receive fermented dairy product containing L. casei shirota or nothing. The main outcome is development of ventilator-associated pneumonia (VAP)

NCT ID: NCT01297894 Recruiting - Drug Safety Clinical Trials

Colistin Versus Colistin Plus Fosfomycin for Infections Caused by MDR Acinetobacter Baumannii

Start date: June 2010
Phase: Phase 3
Study type: Interventional

In Siriraj Hospital, colistin alone for treatment of MDR A. baumannii contributed to mortality 45% Fosfomycin is an antimicrobial which has activity against gram-negative bacterial including MDR A. baumannii In this study, we compare the clinical and microbiologicalresponse of colistin alone versus colistin plus fosfomycin in treatment of A. baumannii infected patients

NCT ID: NCT01297855 Recruiting - Drug Safety Clinical Trials

Colistin Plus Rifampicin in MDR P. Aeruginosa and A. Baumanii

Start date: June 2010
Phase: Phase 3
Study type: Interventional

In Siriraj Hospital, Colistin alone for treatment of MDR. A.baumanii or P.aeruginosa contributed to mortality 45%. In vitro studies revealed synergism of Rifampicin and Colistin. In this study, patients with documented MDR. P.aeruginosa or A.baumanii will be allocated to receive Colistin alone and another group will receive Colistin plus Rifampicin.

NCT ID: NCT01297842 Recruiting - Drug Safety Clinical Trials

Ertapenem Versus Meropenem/Imipenem for ESBL+ Gram-negative Infections

Start date: May 2011
Phase: Phase 4
Study type: Interventional

Adult patients with ESBL-producing Gram negative infections are randomized to receive ertapenem or meropenem/imipenem. Clinical and microbiological responses between both groups are compared.